Get App


Associate Partners

Last Updated : Apr 26, 2019 04:12 PM IST | Source:

Buy Biocon; target of Rs 730: ICICI Direct

ICICI Direct is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 730 in its research report dated April 26, 201

Broker Research @moneycontrolcom
  • bselive
  • nselive
Todays L/H

ICICI Direct's research report on Biocon

Revenues grew 30.7% YoY to Rs 1528.8 crore (I-direct estimate: Rs 1608.0 crore) mainly due to 87.1% YoY growth in biologics to Rs 451 crore (I-direct estimate: Rs 470.0 crore). EBITDA margins improved 644 bps YoY to 26.4% (I-direct estimate: 23.6%) mainly due to strong gross margin performance (68.1% vs. 59.4% in Q4FY18). EBITDA grew 73% YoY to Rs 403 crore against I-direct estimate of Rs 378.8 crore. Adjusted net profit grew 63.9% to Rs 213.7 crore (I-direct estimate: Rs 190.0 crore) mainly due to a strong operational performance and lower tax rate (13.8% vs. 21.6% in Q4FY18).


Biosimilar launches in developed as well as emerging markets and Syngene’s performances remain key levers for the company. On an SoTP basis, we ascribe a target price of Rs 730 per share.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Get Lok Sabha 2019 Live Election Results, constituency-wise tally, news, views and analysis
Follow our Lok Sabha Election Result Live Blog here.
First Published on Apr 26, 2019 04:12 pm
More From
Follow us on
Available On
PCI DSS Compliant